Plate Nº 22 · recorded October 10, 2026
Health & Medicine ResearchReported finding
Single CRISPR Infusion Cut Bad Cholesterol in Half for a Year
A single dose of experimental CRISPR therapy CTX310 cut LDL cholesterol by 52.5% and triglycerides by 47.8% in a 15-patient Phase 1 trial. Results held for one year.
By Marcus Bennett3 min read627 words
In brief
- At the highest 0.8 mg/kg dose, LDL cholesterol fell 52.5% and triglycerides fell 47.8% after 12 months
- The Phase 1 trial enrolled 15 patients and was presented on September 27, 2026 at the European Society of Cardiology meeting
- No serious adverse events were linked to CTX310 during the one-year follow-up
- CTX310 is a one-time infusion that uses CRISPR-Cas9 to disable the ANGPTL3 gene in the liver
- Researchers plan to follow participants for an additional 15 years, per FDA gene-editing guidance
A single infusion of an experimental CRISPR therapy reduced LDL cholesterol by 52.5% and triglycerides by 47.8% in patients with hard-to-treat lipid disorders, according to one-year results from a 15-person Phase 1 trial presented on September 27, 2026.
The study, led by Cleveland Clinic cardiologist Luke Laffin, M.D., tracked participants for 12 months after they received one dose of CTX310, a CRISPR-Cas9 gene-editing treatment. At the highest dose tested, patients sustained an average 52.5% drop in LDL ("bad") cholesterol and a 47.8% drop in triglycerides from their starting levels. The investigators reported no serious adverse events linked to the therapy.
The findings appeared simultaneously at the 2026 European Society of Cardiology annual meeting and in the New England Journal of Medicine.
What does CTX310 actually do?
CTX310 is a one-time intravenous infusion that delivers the CRISPR-Cas9 system to the liver. CRISPR-Cas9 functions as molecular scissors, making precise cuts at a chosen spot in a person's DNA. The therapy targets a liver gene called ANGPTL3, which helps regulate fats circulating in the bloodstream, including LDL cholesterol and triglycerides. Disabling the gene lowers both, which could in theory reduce the risk of heart attacks and strokes.
The trial tested four dose levels, from 0.1 to 0.8 milligrams per kilogram of body weight. Before the infusion, each patient received corticosteroids and antihistamines to limit immune reactions. Researchers then monitored safety and lipid changes over the following year.
How large was the effect?
The headline numbers came from the highest-dose cohort. Participants in that group averaged roughly 50% reductions in both LDL cholesterol and triglycerides 12 months after treatment. Lower doses produced smaller, dose-dependent changes.
Cholesterol and triglyceride levels had already dropped at the two-month mark in earlier data presented in November 2025. The new analysis shows the reductions held steady rather than fading over the next ten months. The 0.8 mg/kg dose led the field, with the 0.1 mg/kg arm showing the smallest shifts.
Is CTX310 safe?
The one-year follow-up turned up no serious adverse events tied to CTX310, according to the investigators. That matters because gene-editing therapies carry theoretical concerns, including off-target DNA edits and long-term unintended effects on other tissues.
"It is encouraging that there were no serious safety events related to CTX310 in the trial and in the year following treatment," Laffin said. "We look forward to continuing to investigate this therapy in a larger number of patients."
Laffin also called the durability of the lipid-lowering effect "impressive" in a Cleveland Clinic statement.
How strong is the evidence?
The study enrolled only 15 patients. That small sample limits how confidently researchers can generalize the results. CTX310 remains experimental, and no one in the trial has been followed long enough to show whether the cholesterol drops translate into fewer heart attacks or longer lives.
The team plans to continue safety monitoring for another 15 years, matching FDA guidance for gene-editing therapies. Larger Phase 2 and Phase 3 trials will be needed to confirm the magnitude of the lipid effect and to compare CTX310 against standard drugs such as statins and PCSK9 inhibitors.
Who paid for the trial?
CRISPR Therapeutics AG, the Swiss company based in Zug that developed CTX310, funded the study. Cleveland Clinic has also received research funding from the company, according to the published disclosure statement.
The full author list on the New England Journal of Medicine paper (DOI: 10.1056/NEJMc2609825) includes Stephen J. Nicholls, Russell S. Scott, Peter M. Clifton, Renate Koops, Ashish Sarraju, Shweta Singh, Qiuqing Wang, Kathy Wolski, Huansheng Xu, Jen Nielsen, Naimish Patel, Jason M. Duran, and Steven E. Nissen.
via newsroom.clevelandclinic.org (Original)
More from Marcus Bennett
Nearby plates
- CRISPR-edited stem cells engrafted in all 30 patients in blood cancer trial
- Gene Editing Converts High-Risk Alzheimer's Gene into Safer Form
- High-Fat Diet Fuels Colon Cancer Spread Through YAP1 Pathway
- Roche Halts Two Huntington's Disease Drug Programmes
- Alzheimer's Drug Developers Accuse Trial Sites of Faking Data